Acousia Therapeutics

About:

Acousia Therapeutics is a privately held biotech company.

Website: http://www.acousia.com/

Top Investors: KfW, Axxam, LBBW VC, Boehringer Ingelheim Venture Fund, Bregua

Description:

Acousia Therapeutics GmbH is a privately held biotech company based in Tübingen, Germany. Acousia has experience and expertise in identifying and developing small molecule drug candidates for the treatment of hearing loss. Sensory hair cells are the key cells for hearing in the inner ear. Acousia`s approach will help to replace lost hair cells by cellular regeneration originating from supporting cells. ASpherecousia is developing drugs for local application, which will restore hearing in patients who have lost their hearing ability induced by various reasons, e.g. noise trauma, treatment with ototoxic drugs or sudden deafness. In addition, these therapies will have the potential to treat the age-related decrease in hearing capacity.

Total Funding Amount:

12.5M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Tübingen, Baden-Wurttemberg, Germany

Founded Date:

2012-01-01

Contact Email:

info(AT)acousia.com

Founders:

Hubert Löwenheim, Karl-Heinz Wiesmüller

Number of Employees:

1-10

Last Funding Date:

2024-01-09

IPO Status:

Private

Industries:

© 2025 bioDAO.ai